Data from microarray studies have been used to develop predictive models for treatment outcome in breast cancer, such as a recently proposed predictive model for antiestrogen response after tamoxifen treatment that was based on the expression ratio of two genes. We attempted to validate this model on an independent cohort of 58 patients with resectable estrogen receptorpositive breast cancer. We measured expression of the genes HOXB13 and IL17BR with real time -quantitative polymerase chain reaction and assessed the association between their expression and outcome by use of univariate logistic regression, area under the receiver-operating-characteristic curve (AUC), a two-sample t test, and a Mann -Whitney test. We also applied standard supervised methods to the original microarray dataset and to another independent dataset from similar patients to estimate the classifi cation accuracy obtainable by using more than two genes in a microarray-based predictive model. We could not validate the performance of the two-gene predictor on our cohort of samples (relation between outcome and the following genes Several studies have demonstrated that breast cancers with distinct pathologic features can be recognized by their gene expression profi le ( 1 -11 ) . Microarrays have been used to identify expression patterns capable of predicting outcome or response after specifi c treatments such as tamoxifen, which is a standard adjuvant treatment for patients with primary, estrogen receptor -positive breast cancer ( 12 , 13 ) . Currently, many patients do not respond to treatment, and so additional biomarkers predictive of treatment failure within endocrineresponsive diseases are required.
Several studies have demonstrated that breast cancers with distinct pathologic features can be recognized by their gene expression profi le ( 1 -11 ) . Microarrays have been used to identify expression patterns capable of predicting outcome or response after specifi c treatments such as tamoxifen, which is a standard adjuvant treatment for patients with primary, estrogen receptor -positive breast cancer ( 12 , 13 ) . Currently, many patients do not respond to treatment, and so additional biomarkers predictive of treatment failure within endocrineresponsive diseases are required.
Recently, a tamoxifen-response predictive model consisting of only two genes has been described ( 14 ) . By using microarray gene expression profi les of 60 tamoxifen-treated patients, HOXB13 and IL17BR were identifi ed as the two genes whose expression ratio predicts clinical outcome. This fi nding was validated by use of real time -quantitative polymerase chain reaction (RT-QPCR) on an independent set of 20 formalinfi xed, paraffi n-embedded samples by correctly classifying the outcomes of 16 patients ( P = .01). However, by considering the data from relapsed and diseasefree patients separately, although the probability of obtaining such a correct classifi cation by chance remained low for disease-free patients (nine of 10 correctly classifi ed, P = .02; 95% confidence interval [CI] for the proportion of correctly classifi ed samples = 0.55 to 0.99), this estimate increased drastically for relapsed patients (seven of 10 correctly classifi ed, P = .34; 95% CI = 0.35 to 0.93). Although the proposed predictive model is very appealing from clinical and practical points of view because of its potential straightforward application in many laboratories, the results of the validation set (i.e., the statistically nonsignifi cant results for the relapsed patients) indicate that a larger validation set is required.
For this reason, we applied this twogene predictive model for relapse to a dataset derived from a cohort of 58 patients with early-stage, estrogen receptorpositive primary breast cancer who were treated at the Istituto Nazionale Tumori between March 1, 1991, and December 31, 1997, with radical or conservative surgery plus radiotherapy followed by adjuvant monotherapy with tamoxifen (median treatment duration = 60 months, range = 27 -84 months). All patients signed an informed consent to donate any tissue leftover after diagnostic procedures to Istituto Nazionale Tumori. A tumor was classifi ed as estrogen receptor positive if the ligand binding assay detected more than 10 fmol of estrogen bound per mg of total protein. Disease recurred with distant metastasis in 18 patients (16 patients as a fi rst event and two as a second event after local-regional recurrence) of the 58 patients within a median time of 31 months (range = 14 -43 months) from surgery. Forty of the 58 patients were disease free after a median time of 93 months (range = 70 -125 months).
Clinical and pathobiologic details of these 58 patients are presented in supplemental Table 1 (Available at: http:// jncicancerspectrum.oupjournals.org/jnci/ content/vol97/issue12 ). Most patients were older than 50 years of age (93.1%) and had lymph node -positive disease (77.5%; 53.5% had one to three positive lymph nodes and 24.0% had more than three positive lymph nodes). Their tumors were larger than 2 cm (62.1% of tumors), were progesterone receptor positive (79.3% of tumors; i.e., more than 25 fmol of progesterone bound per mg of total protein by ligand binding assay), and were HER-2/neu negative (77.6% of tumors). HER-2/neu status was immunohistochemically assessed with polyclonal antibody against p185 HER2 protein (1:2000 dilution, DAKO, Milan, Italy) and defi ned as positive when strong membrane labeling was observed. A limitation of any validation study on independent cohorts can be related to having a different mixture of case patients than that of the original study. Compared with the previously described cohort ( 14 ) , our cohort had a prevalence of tumors that were lymph node positive (77.5% vs. 47.2%), HER-2/neu positive (20.7% vs. 5.4%), and larger than 2 cm (62.1% vs. 47.2%).
RT-QPCR used TaqMan gene expression assays for the following genes: HOXB13 labeled with FAM-MGB (a 6-carboxyfl uorescein fl uorescent dye and a minor groove binding [MGB] molecule attached to the 3 ′ end, which stabilizes the probe annealing; product Hs00197189), IL17BR labeled with FAM-MGB (product Hs00218889), and human GAPDH VIC-MGB (VIC is a proprietary fl uorescent dye; product 4326317E), a housekeeping gene used for normalization (Applied Biosystems, Foster City, CA). Gene expression data were quantifi ed as described by the manufacturer and log-transformed ( Fig. 1 , A , and raw data in supplemental Table 2 ; available at http://jncicancerspectrum.oupjournals. org/jnci/content/vol97/ issue12 ).
We followed the procedures as previously outlined ( 14 ) to evaluate the association between the expression of the two genes and outcome with a twosided t test with unequal variances, with an area under the receiver-operatingcharacteristic curve (AUC) analysis, and with re-estimated univariate logistic models because the original models were not reported. In addition to a t test, the nonparametric Mann -Whitney test was also considered to avoid making assumptions on the distribution of expression data, which departed from normality for HOXB13.
However, our analyses of this independent set of samples did not fi nd any statistically signifi cant association between the gene expression of HOXB13, IL17BR or their ratio and outcome after tamoxifen treatment (e.g., from univariate logistic regression, for HOXB13 odds ratio [OR] = 1.04, 95% confi dence interval [CI] = 0.92 to 1.16, P = .54; for IL17BR, OR = 0.69, 95% CI = 0.40 to 1.20, P = .18; and for HOXB13/IL17BR, OR = 1.30, 95% CI = 0.88 to 1.93, P = .18). Results of the latter model, with the overlapping estimated probabilities of recurrence for disease-free patients and relapsed patients are shown in Fig. 1 , B . Similar P values were obtained from t tests, Mann -Whitney tests, and AUC analyses ( Table 1 ) .
Because of this contradictory result, we investigated the feasibility of predicting recurrence after tamoxifen treatment by making thorough use of published microarray data. We applied standard supervised analysis on the laser-capture microdissections dataset from Ma et al. ( 14 ) (hereafter dataset TAM1) and on a subset of tamoxifen-treated patients with estrogen receptor -positive tumors who had not undergone chemotherapy and who had a known recurrence status from another published cohort of patients ( 6 ) (hereafter dataset TAM2) that refl ects the clinical characteristics of patients in TAM1. Both of these datasets used duallabeling competitive-hybridization technologies (cDNAs and oligonucleotides) and the Universal Human Reference RNA (Stratagene, La Jolla, CA). Because we lacked independent validation sets, estimates of prediction error rates were obtained by use of 10-fold crossvalidation, a sampling method that divides the data into 10 parts, each of which is set aside to test the accuracy achieved by using the prediction rule built on the remaining data ( 7 , 15 , 16 ) . As the prediction algorithm, we used diagonal linear discriminant analysis, a method that showed good performance for microarray data ( 17 , 18 ) . The number of genes included in the model was estimated by cross-validation, repeatedly performing feature selection for each training set ( 19 ) by use of the highest univariate two-sided pooled variance t statistic. This procedure enabled us to assess the sensitivity of the classifi er to the number of selected genes ( Fig. 1, C ) and to obtain an estimate of 30 genes for TAM1 and six genes for TAM2. To obtain a correct estimate of the misclassifi cation error rate associated with these predictive models, we performed a full cross-validation study that took into account the fact that the number of genes included in the model was not specifi ed a priori. The resulting error rates were 39% for TAM1 and 46% for TAM2. Notice how these error rates would have been misleadingly underestimated if this full cross-validation had not been considered (25% for TAM1 and 24% for TAM2; Fig. 1, C ) . When only two genes were selected in TAM1, the misclassifi cation error rate was 37% [ P = .325, for the permutation test on the cross-validated ). CI = confi dence interval based on normality assumption. t test P = P value from two-sided t test with unequal variances; Mann -Whitney P = P value from two-sided MannWhitney test.
† Area under the receiver-operating characteristic (AUC) curve. Standard errors (SEs) were obtained by a bootstrap procedure ( B = 200), allowing AUC to be less than 0.5. 95% CIs were obtained as AUC ± 1.96 SE. P values were calculated for the null hypothesis AUC = 0.5; alternative AUC ≠ 0.5.
‡ Regression coeffi cient from univariate logistic regression (coding: 0 = disease-free; 1 = relapsed). P is the P value from two-sided Wald test. misclassifi cation error rate based on 2000 permutations ( 20 ) ], indicating that two genes cannot predict a patient's response to tamoxifen treatment.
In conclusion, in our cohort of patients we failed to validate the predictive model proposed by Ma et al. ( 14 ) . Furthermore, building predictors for tamoxifen treatment by use of two independent microarray datasets did not provide promising results. These facts probably highlight the heterogeneous nature of the Fig. 1 . Distributions of HOXB13 and IL17BR, associated predicted probabilities of recurrence estimated by logistic regression model, and average cross-validated misclassifi cation error rates on two independent microarray data sets. A) Boxplots of the log-transformed amounts of targets for HOXB13 and IL17BR and their standardized ratio stratifi ed by recurrence status on the Istituto Nazionale Tumori cohort. DF = disease free; R = recurrent. Total RNA was extracted from frozen samples with Trizol (Life Technologies, Frederick, MA) and treated with DNase. For cDNA synthesis, 2 μ g of total RNA was reverse-transcribed and amplifi ed in duplicate on an ABI PRISM 7700, according to the manufacturer's instructions. Relative quantitation of gene expression from real time -quantitative polymerase chain reaction (RT-QPCR) data were obtained by following the manufacturer's instructions. The ratio of the amounts of targets, HOXB13/IL17BR, was obtained after standardizing both genes separately (subtracting the mean and dividing by standard deviation). All the analyses were carried out with R, a language and environment for statistical computing ( 25 ) and receiver operating characteristic curves were fi tted with the Bioconductor ( 26 ) roc library. The boxplots represent the fi rst quartile (i.e., lower edge of the box), median (i.e., bar inside the box), third quartile (i.e., upper edge of the box), and minimum and maximum (i.e., horizontal lines). If any points are at a greater distance from the quartiles than 1.5 times the interquartile range (IQR), these are plotted individually and horizontal bars represent a distance of 1.5 times IQR from the upper or lower quartile. B) Probability of experiencing recurrence, stratifi ed by recurrence status, estimated by logistic model including HOXB13/IL17BR as a covariate for the Istituto Nazionale Tumori cohort. C) Average 10-fold cross-validation (CV) misclassifi cation error rates were determined by use of diagonal linear discriminant analysis (DLDA) of the TAM1 ( 14 ) and TAM2 ( 6 ) datasets on decreasing number of genes (from 500 to 250 at intervals of 50, from 250 to 150 at 10, from 150 to 100 at 5, and from 100 down to 2 the number was decreased one at a time). The superimposed curve was fi tted by use of a lowess smoother, error bars represent average 10-fold cross-validation misclassifi cation error rates plus or minus their standard error. Data sets were prepared as follows. Dataset TAM1 contained 60 samples (of which 59 were estrogen receptor-positive) from primary breast cancers from patients treated with tamoxifen monotherapy for 5 years (28 with recurrent disease and 32 who were disease free). Dataset TAM2 contained 99 breast cancer samples, 44 of which were estrogen receptor-positive by both a ligand binding assay and immunohistochemistry and were from patients who had not undergone chemotherapy and who had been treated with tamoxifen (16 with recurrent disease and 28 who were disease free). Raw data for dataset TAM1 were downloaded from the NCBI Gene Expression Omnibus (GEO) database at http://www.ncbi.nlm.nih.gov/geo/ (accession number GSE1378) and processed as previously described ( 14 ) , so that the raw background-corrected signals were normalized with a lowess transformation. The processed and normalized log ratios for dataset TAM2 were downloaded from the supporting information available from the publishers' web site at http://www. pnas.org/cgi/content/full/1732912100/DC1 . Datasets were fi ltered according to the methods reported in the original publications. For the TAM1 dataset, only the fi ltered dataset that was based on overall variance of each gene (top 75th percentile) was used; this procedure resulted in a 5644 × 60 gene expression matrix. For the TAM2 data set, the whole set with no more than 50% missing values per gene was used; this procedure resulted in a 7525 × 44 gene expression matrix. Missing values in both data sets were imputed by the k -nearest neighbor method ( k = 10), as previously described ( 24 ) , and fi nally data were standardized (all rows [genes] set to 0 = mean and 1 = standard deviation) before applying the cross-validation procedure. Microarray data preparation was done by use of the Bioconductor ( 26 ) Biobase library, multtest was used for the t tests, pamr was used for the missing value imputation and for creating balanced folds during the cross-validations, and sma [R (25) library] was used for the diagonal linear discriminant analysis. underlying disease and, hence, the need for microarray data sets from much larger and/or more homogeneous cohort of samples to build more reliable predictive models. For the time being, because of the relatively small sample sizes of microarray experiments, this challenging task may only be circumvented by thoughtful experiment design ( 21 , 22 ) and by providing public access to published microarray data ( 23 ) , which will drive reproducible results and accelerate the design of appropriate meta-analytical techniques for integrating data from different studies. We believe that it is also crucial that microarray data be viewed as a valuable and rich source of additional information that can supplement information from clinical and pathobiologic markers toward the goal of developing effi cient and subject-tailored treatment strategies.
